Moneycontrol
HomeNewsBusinessStartupCoronavirus pandemic | In survival mode, startups agree to tougher terms for funds

Coronavirus pandemic | In survival mode, startups agree to tougher terms for funds

Economic uncertainty, falling valuations force some companies to give investors a greater say.

May 12, 2020 / 11:04 IST
Story continues below Advertisement
Representative Image

The coronavirus pandemic is making it difficult for some startups to raise funds, forcing them to agree to tougher terms as investors get cautious and seek a greater say in an uncertain economic climate, source have told Moneycontrol.

Startups and venture capitalists (VCs) always drive a hard bargain but some founders, who desperately need money to survive the lockdown, are giving away rights to investors they otherwise would not.

Story continues below Advertisement

"While founders have become more aware and aggressive about their rights over the years, COVID is making them negotiate less because the money is more important than the terms and valuation it comes with--it is to ensure survival,” said Roma Priya, founder of Burgeon Law, a startup focused law firm. COVID-19 is the respiratory illness caused by the coronavirus.

For early to growth-stage deals, valuations have fallen 20-30 percent. Some founders are not being too stringent about voting rights, transfer of shares and sharing information with investors, sources said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show